UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

ABCB4

Synonyms: ABC21, GBD1, MDR2, MDR2/3, MDR3, PFIC-3, PGY3

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura    0.0000887
Kidney Nishimura    0.000425
Liver* Nishimura    0.150
Placenta Nishimura    0.000122
Small Intestine Nishimura    0.000614
Kidney Mean across all PMT Samples BLQ
Liver* Mean across all PMT Samples 5.061
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Digoxin ND Nucleotide trapping assay with Sf9-MDR3 membranes Smith, 2000
Paclitaxel ND Nucleotide trapping assay with Sf9-MDR3 membranes Smith, 2000
Verapamil ND Nucleotide trapping assay with Sf9-MDR3 membranes Smith, 2000
Vinblastine ND Nucleotide trapping assay with Sf9-MDR3 membranes Smith, 2000

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
Cyclosporine ND Not applicable nucleotide trapping with MDR3-expressing Sf9 membranes Smith, 2000
Paclitaxel ND Not applicable nucleotide trapping with MDR3-expressing Sf9 membranes Smith, 2000
Valspodar ND Not applicable nucleotide trapping with MDR3-expressing Sf9 membranes Smith, 2000
Verapamil ND Not applicable nucleotide trapping with MDR3-expressing Sf9 membranes Smith, 2000
Vinblastine ND Not applicable nucleotide trapping with MDR3-expressing Sf9 membranes Smith, 2000

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner